Recent studies indicate that AHR inhibition might be a suitable strategy to enhance the efficacy of immunotherapeutic applications against malignant melanoma and, in addition, AHR modulation may affect melanoma resistance against protein kinase inhibitors frequently used in the clinical routine. Here, WEE1 is linked to melanoma.